ArticleFrontiers in cardiovascular medicine2026
Dose reduction and discontinuation of sacubitril/valsartan over time in patients undergoing maintenance hemodialysis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the therapeutic effects and dose adjustment patterns of sacubitril/valsartan (SV) over time in patients undergoing maintenance hemodialysis (HD). Methods: The clinical data of end-stage renal disease patients receiving maintenance HD at our center were retrospectively reviewed. A total of 151 patients treated with SV were included. All patients were followed up regularly in the dialysis outpatient clinic. The clinical characteristics, biochemical parameters, and echocardiographic measurements were collected at baseline and during follow-up. The efficacy, safety, and dose adjustment patterns of SV therapy were analyzed. Results: A six-month observation period was selected for analysis to ensure adequate follow-up while maximizing the number of eligible patients included in the study. SV dose reduction was observed in 62 patients, and 48 patients had discontinued concomitant antihypertensive medications. The greatest reduction in the proportion of patients receiving SV combined with other antihypertensive agents occurred at the fourth month after dialysis initiation (39.8%). Patients receiving SV without dose reduction and in combination with other antihypertensive drugs had higher interdialytic and intradialytic blood pressure, when compared with patients receiving SV monotherapy or reduced/discontinued SV. The multivariate analysis identified diabetes mellitus [odds ratio [OR]: 3.085, 95% confidence interval [CI]: 1.137-8.376, Conclusion: In real-world practice, the dose reduction or discontinuation of SV is common in HD patients. Clinicians should carefully balance individual risks and benefits, apply SV with caution, and closely monitor patients receiving this therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.